Fig. 4

Losartan blocks the enhanced HPSLF migration in vitro. A Western blot analysis of Myosin IIB, phospho-p38, and p38 protein expression in HPSLF (n = 3 technical replicates) treated with vehicle (DMSO) or with losartan (100 nM). β-Actin was used as a loading control. B Ratio of phospho-p38 to p38 density and C Myosin IIB to β-Actin density expressed as fold-change relative to DMSO. D Representative microscopy images of scratch assays at 0, 12, and 24 h after gaps were generated. Scratch assays were performed with HPSLF (n = 3 technical replicates) treated with vehicle (DMSO) or losartan (100 nM). E Quantitative analysis of the migration potential. The rate of fibroblast migration was determined by calculating the percentage of open wound area at the indicated time points to that of the corresponding initial scratch. Data are expressed as mean ± SEM of three independent experiments. B, C Data analyzed using students t-test *P < 0.5, ***P < 0.001. E Data analyzed using two-way mixed ANOVA **P < 0.01